Alpha 1 Antitrypsin Deficiency & COPD
Alpha-1 antitrypsin deficiency is a genetic disorder that is passed on in families and affects the lungs, liver and skin. When this condition affects the lungs, it causes COPD. There is no cure, but treatment can help people with Alpha-1 antitrypsin deficiency manage their symptoms and live a better life. The preliminary symptoms are shortness of breath following mild activity, reduced ability to exercise, and wheezing. Other signs and symptoms include unintentional weight loss, recurring respiratory infections, fatigue, and rapid heartbeat upon standing. Affected individuals often develop emphysema, which is a lung disease caused by damage to the small air sacs in the lungs. Alpha-1 antitrypsin deficiency accounts for 1 to 2% of all cases of chronic obstructive pulmonary disease.
Related Conference of Alpha 1 Antitrypsin Deficiency & COPD
5th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
17th International Conference on Chronic Obstructive Pulmonary Disease
Alpha 1 Antitrypsin Deficiency & COPD Conference Speakers
Recommended Sessions
- Asthma
- Chronic Obstructive Pulmonary Disease
- Alpha 1 Antitrypsin Deficiency & COPD
- Cardiopulmonary Disorders
- Clinical management of severe acute respiratory infection
- COVID-19 Treatment and Recovery
- Covid19 Vaccine and Lung Immunopathology
- Cystic Fibrosis
- Depression and anxiety in COPD
- Diagnosis and Treatment of COPD
- Digital Health in Respiratory Care
- Effect of COVID-19 on Lungs
- Genetic risk factor of COPD
- Idiopathic Pulmonary Fibrosis
- Innate Immunity and Lung Fibrosis
- Investigational Drugs and Other Therapies in the treatment of Respiratory Disease
- Lung cancer
- Lung Cancer Diagnosis & Treatment
- Pathology and Clinical Management of COPD
- Pneumonia
- Pulmonary Rehabilitation
- Respiratory Diseases
- Severe Acute Respiratory Syndrome (SARS)
- Sleep apnea
- Tuberculosis
Related Journals
Are you interested in
- Advances in Tuberculosis Diagnosis, Treatment, and Prevention - Tuberculosis-2025 (France)
- Asthma - Pulmonary Meet 2025 (France)
- Asthma and COPD - COPD_2025 (Spain)
- Chronic Bronchitis - Pulmonary Meet 2025 (France)
- Chronic Obstructive Pulmonary Disease - COPD_2025 (Spain)
- Co-Morbidities of COPD - COPD_2025 (Spain)
- Community-based Approaches to TB and Lung Health Awareness - Tuberculosis-2025 (France)
- COPD - Pulmonary Meet 2025 (France)
- COPD and Cardiovascular Diseases - COPD_2025 (Spain)
- COPD Complications - COPD_2025 (Spain)
- COPD Exacerbations - COPD_2025 (Spain)
- COPD Pathogenesis - COPD_2025 (Spain)
- COPD Therapeutics - COPD_2025 (Spain)
- COPD: Sign and Symptoms - COPD_2025 (Spain)
- Cystic Fibrosis - Pulmonary Meet 2025 (France)
- Depression and anxiety in COPD - COPD_2025 (Spain)
- Digital Health Technologies for Respiratory Disease Management - Tuberculosis-2025 (France)
- Drug Discovery of COPD - COPD_2025 (Spain)
- Early Diagnosis and Biomarkers in Respiratory Diseases - Tuberculosis-2025 (France)
- Emerging Respiratory Threats and Pandemic Preparedness - Tuberculosis-2025 (France)
- Emphysema - Pulmonary Meet 2025 (France)
- Epidemiology of COPD - COPD_2025 (Spain)
- Genetic risk factor of COPD - COPD_2025 (Spain)
- Genetics and Susceptibility to Tuberculosis and Lung Diseases - Tuberculosis-2025 (France)
- Global Efforts to Eliminate Tuberculosis by 2030 - Tuberculosis-2025 (France)
- Hospital-acquired Infections and Respiratory Care - Tuberculosis-2025 (France)
- Impact of Smoking and Environmental Factors on Lung Health - Tuberculosis-2025 (France)
- Infectious Respiratory Diseases - Pulmonary Meet 2025 (France)
- Interstitial lung disease - Pulmonary Meet 2025 (France)
- Latent Tuberculosis: Diagnosis, Treatment, and Control - Tuberculosis-2025 (France)
- Lung cancer - COPD_2025 (Spain)
- Lung Cancer - Pulmonary Meet 2025 (France)
- Lung Health: Emerging Trends and Challenges - Tuberculosis-2025 (France)
- Lung problems - Pulmonary Meet 2025 (France)
- Lung transplantation - Pulmonary Meet 2025 (France)
- Multidrug-Resistant Tuberculosis (MDR-TB) and Novel Therapies - Tuberculosis-2025 (France)
- Neonatal and Maternal Respiratory Health - Tuberculosis-2025 (France)
- Novel Therapies and Drug Development for Tuberculosis - Tuberculosis-2025 (France)
- Pathophysiology of COPD - COPD_2025 (Spain)
- Pediatric Pulmonary, Critical care and Sleep - COPD_2025 (Spain)
- Pediatric Tuberculosis and Respiratory Health - Tuberculosis-2025 (France)
- Pleural Diseases - Pulmonary Meet 2025 (France)
- Prevention and Control of Respiratory disease - Pulmonary Meet 2025 (France)
- Pulmonary diseases-treatment and therapies - COPD_2025 (Spain)
- Pulmonary Hypertension - Pulmonary Meet 2025 (France)
- Pulmonary Hypertension - COPD_2025 (Spain)
- Pulmonary Rehabilitation - Pulmonary Meet 2025 (France)
- Pulmonary Rehabilitation and Holistic Care for Respiratory Diseases - Tuberculosis-2025 (France)
- Pulmonary vascular disease - Pulmonary Meet 2025 (France)
- Pulmonology - Pulmonary Meet 2025 (France)
- Respiratory Disorders - Pulmonary Meet 2025 (France)
- Respiratory Infections and Global Public Health Concerns - Tuberculosis-2025 (France)
- Respiratory Infections and Global Public Health Concerns - Tuberculosis-2025 (France)
- Respiratory Tract Infections - Pulmonary Meet 2025 (France)
- Role of Artificial Intelligence in Tuberculosis Diagnosis - Tuberculosis-2025 (France)
- Self-Management and Prevention of COPD - COPD_2025 (Spain)
- Sleep-Related Respiratory Disorders - Pulmonary Meet 2025 (France)
- Tuberculosis - Pulmonary Meet 2025 (France)
- Tuberculosis and HIV Co-infection: Challenges and Treatment - Tuberculosis-2025 (France)
- Tuberculosis Prevention and Global Public Health Strategies - Tuberculosis-2025 (France)
- Types of COPD - COPD_2025 (Spain)